Research teams - Stabilis 4.0

Research teams - Nippon Medical School Hospital, Department of Pharmacy

Nippon Medical School Hospital, Department of Pharmacy

Tokyo

References

(4)

Y-site injection physical compatibility of remdesivr with select intravenous drugs used in palliative care and for treating coronavirus disease 2019.
Kondo M, Genpei M, Watanabe K, Yoshida M, Tagui N, Fukao S, Sugaya K, Takase H. (kondomasayoshi@nms.ac.jp)
Journal of Nippon Medical school - 2023 -

Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration.
Kondo M, Yoshida N, Yoshida M, Tanaka C, Tagami T, Horik K, Sugaya K, Takase H (kondomasayoshi@nms.ac.jp)
Am J Health-Syst Pharm - 2022 - https://doi.org/10.1093/a

Physical compatibility of nafamostat with analgesics, sedatives, and muscle relaxants for coronavirus disease treatment.
Kondo M, Nagano M, Yoshida M, Yoshida N, Tagui N, Yoshida M, Sugaya K, Takase H. (kondomasayoshi@nms.ac.jp)
Journal of Nippon Medical school - 2021 -

Development of New Mixing Method of Busulfex® Injecton for the Purpose of Improvement of Medical Safety Method; The Prefilled Syringe Method.
Senoo M, Tajika K, Shimizu H, Hamada M, Dobashi Y, Dan K, Katayama S. (senoo@nms.ac.jp)
Yakugaku Zasshi - 2009 - 129, 6: 767-771.

Molecules studied

(16)

		Busulfan
		Dexmedetomidine
		Fentanyl citrate
		Furosemide
		Heparin sodium
		Hydromorphone hydrochloride
		Midazolam hydrochloride
		Morphine hydrochloride
		Nafamostat
		Octreotide acetate
		Oxycodone hydrochloride
		Remdesivir
		Remifentanil hydrochloride
		Remimazolam
		Rocuronium bromide
		Vecuronium bromide